Wladimir Hogenhuis
Directeur/Bestuurslid bij REZOLUTE, INC.
Vermogen: 85 002 $ op 30-04-2024
Profiel
Wladimir Hogenhuis is currently the President, Chief Executive Officer & Director at Driver Bioengineering, Inc., an Independent Director at Rezolute, Inc., a Director at GATT Technologies BV, and a Director at IHP Therapeutics, Inc. He was previously a Director at Vision 2020, the General Manager-Neuroscience at Merck & Co., Inc., the Chief Operating Officer at Ultragenyx Pharmaceutical, Inc., and the Senior Vice President at GSK Plc.
Hogenhuis holds a doctorate from the University of Leiden and an MBA from The Wharton School of the University of Pennsylvania.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
REZOLUTE, INC.
0.08% | 18-03-2024 | 32 693 ( 0.08% ) | 85 002 $ | 30-04-2024 |
Actieve functies van Wladimir Hogenhuis
| Bedrijven | Functie | Begin |
|---|---|---|
| REZOLUTE, INC. | Directeur/Bestuurslid | 02-03-2021 |
GATT Technologies BV
 GATT Technologies BV Medical SpecialtiesHealth Technology GATT Technologies BV develops a soluble surgical tape. It manufactures a polymer-based general adhesive tissue tape that is used as a surgical sealant for various surgical applications. The company was founded in August 2011 by Johan Bender and André de Lege and is headquartered in Nijmegen, the Netherlands. | Directeur/Bestuurslid | 01-05-2020 |
| IHP Therapeutics, Inc. | Directeur/Bestuurslid | - |
Driver Bioengineering, Inc.
 Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Driver Bioengineering, Inc. develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor. It engages in building control systems for chimeric antigen receptor (CAR) T-cell therapeutics. The company was founded by Gusti Zeiner, Christina Smolke and Benjamin Wang on May 12, 2015 and is headquartered in Menlo Park, CA. | Algemeen Directeur | 28-04-2022 |
Eerdere bekende functies van Wladimir Hogenhuis
| Bedrijven | Functie | Einde |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Operationeel Directeur | 10-01-2020 |
| GSK PLC | Corporate Officer/Principal | 01-09-2018 |
| Vision 2020 | Directeur/Bestuurslid | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Opleiding van Wladimir Hogenhuis
| University of Leiden | Doctorate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| REZOLUTE, INC. | Health Technology |
| GSK PLC | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
GATT Technologies BV
GATT Technologies BV Medical SpecialtiesHealth Technology GATT Technologies BV develops a soluble surgical tape. It manufactures a polymer-based general adhesive tissue tape that is used as a surgical sealant for various surgical applications. The company was founded in August 2011 by Johan Bender and André de Lege and is headquartered in Nijmegen, the Netherlands. | Health Technology |
| IHP Therapeutics, Inc. | |
Driver Bioengineering, Inc.
Driver Bioengineering, Inc. Medical SpecialtiesHealth Technology Driver Bioengineering, Inc. develops modular, drug-responsive, titratable, ribozyme based control devices for chimeric antigen receptor. It engages in building control systems for chimeric antigen receptor (CAR) T-cell therapeutics. The company was founded by Gusti Zeiner, Christina Smolke and Benjamin Wang on May 12, 2015 and is headquartered in Menlo Park, CA. | Health Technology |
| Vision 2020 |
